Actionable genomic alterations and drug selection
tumor
TUMOR
Potentially eligible patients must have at least one of the actionable genomic alterations (somatic or germline) listed in Table identified in their tumor and no variants conferring resistance to the relevant targeted anticancer therapy. The genomic alteration may be identified by any tumor genomic test or immunohistochemistry test performed on any type of tumor specimen (fresh frozen, RNAlater-preserved, formalin fixed paraffin embedded (FFPE)) or on ctDNA obtained from plasma (liquid biopsy) in a laboratory accredited by the competent local regulatory authority. Central confirmation of the actionable genomic alteration is performed retrospectively but is not a requisite for initiation of treatment. If more than one actionable genomic alteration is identified, the drug with the higher level of evidence supporting its use is preferred [